471 patents
Page 2 of 24
Utility
Combinations of Diacylglycerol Acyltransferase 2 Inhibitors and Acetyl-coa Carboxylase Inhibitor
21 Dec 23
Described herein are pharmaceutical compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto.
Neeta Balkrishan Amin, Arthur James Bergman, Roberto Arnaldo Calle, Robert Gregory Dullea, David James Edmonds, William Paul Esler, Kevin James Filipski, James Richard Gosset, Albert Myung Kim, Jeffrey Allen Pfefferkorn, Patrick Robert Verhoest
Filed: 22 Feb 21
Utility
Combination of a Poxvirus Encoding HPV Polypeptides with an ANTI-PD-L1 Antibody
21 Dec 23
The present invention relates to a combination of a) a poxvirus vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and an immunostimulatory cytokine, and b) an anti-PD-L1 antibody or antigen-binding fragment thereof, for use in the treatment of an HPV-positive cancer, wherein a first administration of said poxvirus is performed 5 to 10 days before the first administration of said anti-PD-L1 antibody, and subsequent administrations of said poxvirus and anti-PD-L1 antibody are performed.
Kaidre BENDJAMA, Maud BRANDELY-TALBOT, Annette TAVERNARO
Filed: 21 Sep 20
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
21 Dec 23
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Filed: 20 Jan 23
Utility
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
21 Dec 23
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof.
Paul Wayne Brown, Kaushik Dutta, Jason Arnold Lotvin, Kelly Jeffrey Sackett
Filed: 4 Nov 21
Utility
ANTI-TNFR2 Antibodies and Methods of Use Thereof
21 Dec 23
The present disclosure provides antibodies that bind to TNFR2 as well as uses of the antibodies and associated methods.
Todd Douglas ASHWORTH, Yue LIU, Nicholas Andrew MARZE, Virginie MCMANUS
Filed: 25 May 23
Utility
Crystal-free High-concentration Testosterone Cypionate Formulations
14 Dec 23
A pharmaceutical formulation for parental use comprising testosterone cypionate with a concentration of 200 mg/mL, benzyl benzoate with a concentration of 25%-35% v/v, cottonseed oil, and a preservative.
Christopher Lee Beltz
Filed: 26 Oct 21
Utility
Methods for Purification of AAV Vectors by Anion Exchange Chromatography
14 Dec 23
The present disclosure provides methods for purifying a recombinant AAV (rAAV) vector from a solution by anion-exchange chromatography (AEX) to produce an eluate enriched for full capsids and depleted of empty capsids.
Alexander BERRILL, William S. KISH, John R. LIGHTHOLDER, Matthew K. ROACH, William B. WELLBORN, Tamara ZEKOVIC
Filed: 1 Nov 21
Utility
Peg-free Aqueous Suspensions for Parenteral Administration of a Corticosteroid
7 Dec 23
A parenteral aqueous suspension formulation for corticosteroids without polyethylene glycol (PEG) or Polysorbate (PS) that has better resuspendability, longer stability compared to commercially available formulations, and additionally allows for stable formulations of higher concentrations of corticosteroids that were not previously feasible.
Omar Abdelrahman Salman, Joel Aaron Bergman
Filed: 19 Oct 21
Utility
Compositions Relating to a Mutant Clostridium Difficile Toxin and Methods Thereof
7 Dec 23
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G.K. Donald, Maninder K. Sidhu, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint
Filed: 15 Dec 22
Utility
Chemical Compounds
30 Nov 23
Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
Filed: 24 May 23
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
30 Nov 23
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Filed: 28 Jul 23
Utility
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
30 Nov 23
Martin James WYTHES, Indrawan James MCALPINE, Ryan PATMAN, Eugene Yuanjin RUI, Andrew FENSOME, Andreas MADERNA, Mehran JALAIE, Ketan S. GAJIWALA
Filed: 24 Jul 23
Utility
Methods for purifying bacterial polysaccharides
30 Nov 23
The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
Elizabeth BARANYI, Wei CHEN, Zecheng CHEN, Justin Keith MORAN, Yonghui YUAN
Filed: 19 Oct 21
Utility
Kras G12C Inhibitors
23 Nov 23
The present invention relates to compounds that inhibit KRas G12C.
Matthew Arnold MARX, James Gail CHRISTENSEN, Christopher Ronald SMITH, James F. BLAKE, Laurence E. BURGESS, Mark Joseph CHICARELLI, Adam COOK, Jay Bradford FELL, John P. FISCHER, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Pavel SAVECHENKOV, Tony P. TANG, Guy P.A. VIGERS
Filed: 21 Oct 22
Utility
Anti-lymphotoxin Beta Receptor Antibodies and Methods of Use Thereof
16 Nov 23
Antibodies that specifically bind to LTBR are provided.
James Reasoner APGAR, Bas Joannes Gertrudis BAATEN, Aruna BITRA, Javier Fernando CHAPARRO RIGGERS, Giuseppe DI CARO, Pawel Kamil DOMINIK, Zachary John MABEN, Lidia MOSYAK, Andrew Ross NAGER, Cecilia Marianne ODERUP, Edward Derrick PASCUA, Shahram SALEK-ARDAKANI, Dirk Michael ZAJONC
Filed: 10 May 23
Utility
Benzodiazepine Derivatives Useful In Treating a Respiratory Syncytial Virus Infection
16 Nov 23
Matthew BARRETT, George Stuart COCKERILL, James GOOD, Craig Alex AVERY, Edward James COCHRANE, Stuart Thomas ONIONS, Andrew Joseph WARNER
Filed: 7 Jul 21
Utility
Use Of Perfusion To Enhance Production Of Fed-batch Cell Culture In Bioreactors
16 Nov 23
The invention relates to methods of improving protein production, e.g., large-scale commercial protein production, e.g., antibody production, utilizing a modified fed-batch cell culture method comprising a cell growth phase and a polypeptide production phase.
Gregory Walter HILLER
Filed: 26 Jul 23
Utility
Glycoconjugation Processes and Compositions
9 Nov 23
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
Filed: 21 Jun 23
Utility
Solid Forms of a CDK4 Inhibitor
9 Nov 23
This invention relates to crystalline and amorphous forms of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.
Wesley Dewitt CLARK, Judith Gail DEAL, Brian Matthew SAMAS
Filed: 13 Sep 21
Utility
Kras G12D Inhibitors
9 Nov 23
The present invention relates to compounds that inhibit KRas G12D.
Xiaolun Wang, Matthew Arnold Marx, Shelley Allen, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Michael Christopher Hilton, Dean Russell Kahn, Macedonio Junior Mejia, Phong Nguyen, Spencer Pajk, Martha E. Rodriguez, Pavel Yu Savechenkov, Tony Pisal Tang
Filed: 21 Sep 21